Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q1 2023 · 10-Q
Revenue$557.54M$557.54M+12.0% vs Q1 2022 Net Income-$6.94M-$6.94MN/M vs Q1 2022 EPS Diluted-$0.05-$0.05N/M vs Q1 2022 Gross Profit$178,186,000+2.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flow$139,712,000+16.1% Free Cash Flowderived$130,024,000+18.7% Margins · derivedGross margin32.0%−3.1 pt vs Q1 2022
Operating margin6.2%+1.5 pt vs Q1 2022
Net margin-1.2%+0.5 pt vs Q1 2022
ended Mar 31, 2023 · filed May 9, 2023 · 39 d after period end